CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 277 enrolled
Drug / intervention
Anifrolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04931563
NCT04931563Phase 3Completed
CompareCT.gov

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus

AstraZeneca·interventional·Posted Jun 18, 2021·Updated May 20, 2026

In Brief

A Phase 3 clinical trial evaluating Anifrolumab and placebo for Active Systemic Lupus Erythematosus. Completed, enrolled 277 participants across 65 sites in 6 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActive Systemic Lupus Erythematosus
CountriesChina, Hong Kong, Philippines, South Korea, Taiwan, Thailand
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJun 18, 2021
Enrollment StartSep 13, 2021
Primary CompletionApr 7, 2025
Study CompletionJun 10, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.0 years ago

Interventions

Anifrolumabbiological

Intravenous infusion (IV)

placebodrug

Intravenous infusion (IV)